# OnCo record seed-therapeutics (company). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/companies/seed-therapeutics/>
  a schema:Organization ;
  onco:kind "company" ;
  schema:identifier "seed-therapeutics" ;
  schema:name "SEED Therapeutics"@en ;
  schema:alternateName "SEED Therapeutics, Inc."@en ;
  schema:description "SEED Therapeutics designs molecular glues, tablet drugs that make the cell's own disposal system destroy a chosen protein. Its first cancer drug, ST-01156, removes a protein called RBM39 and is in an early trial for advanced solid tumours, including Ewing sarcoma and liver cancer."@en ;
  schema:url <https://onco.cc/companies/seed-therapeutics/>, <https://seedtherapeutics.com/> ;
  schema:dateModified "2026-10-29"^^xsd:date ;
  schema:citation <https://seedtherapeutics.com/>, <https://seedtherapeutics.com/media/seed-therapeutics-nominated-for-2026-prix-galien-usa-best-start-up-award>, <https://clinicaltrials.gov/study/NCT07197554> ;
  schema:addressCountry "US" ;
  onco:cancers <https://onco.cc/cancers/ewing-sarcoma/>, <https://onco.cc/cancers/hcc/>, <https://onco.cc/cancers/biliary-tract-cancer/>, <https://onco.cc/cancers/neuroblastoma/> ;
  onco:sections <https://onco.cc/fronts/targeted-therapy/>, <https://onco.cc/fronts/drug-discovery/> ;
  onco:technologies <https://onco.cc/technologies/protac-degrader/>, <https://onco.cc/technologies/molecular-glue-platforms/> ;
  onco:targets <https://onco.cc/targets/rbm39/> .